Evidence map›Paper›PMID 40442409›Full record

ArticleThe Journal of antibiotics2025

A novel clotrimazole selenium nano-composite for combating deep dermal Candida albicans infections and virulence genes.

Rana Eshimy, Ahmed I El-Batal, Farag M Mosallam

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of antibiotics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rana EshimyMicrobiology and immunology, Egyptian drug authority, Cairo, Egypt.
Ahmed I El-BatalMicrobiology Lab, Drug Radiation Research Department, Biotechnology Division, National Center for Radiation Research and Technology (NCRRT), Egyptian Atomic Energy Authority, Cairo, Egypt.
Farag M MosallamMicrobiology Lab, Drug Radiation Research Department, Biotechnology Division, National Center for Radiation Research and Technology (NCRRT), Egyptian Atomic Energy Authority, Cairo, Egypt. farag3m2012@gmail.com.ORCID 0000-0003-1784-101X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Traditional antifungal drugs are ineffective against multidrug-resistant Candida infections. The goal of this work is the preparation of Clotrimazole Selenium Nano-composite (CZ-Se-NC) suspension and CZ-Se-NC-gel for combating clotrimazole-resistant Candida albicans (NCRRT-CZR) infection. CZ-Se-NC is prepared by simple homogenization ultra-sonication technique and validated by SEM-EDX mapping, DLS, Zeta potential and FT-IR that confirm formulation of Nano-composite. In vitro results demonstrated that CZ-Se-NC and formulated CZ-Se-NC gel have the same anti-candidal activity showing inhibitory zone values 31.0 ± 0.931 mm, 27.0 ± 1.004 and MIC values 0.625, 1.25 µg ml

Indexed as

Antifungal AgentsCandida albicansCandidiasisCandidiasis, CutaneousClotrimazoleNanocompositesSeleniumAnimalsBiofilmsDrug Resistance, FungalFemaleMiceMicrobial Sensitivity TestsVirulenceAntifungal AgentsClotrimazoleSelenium

Identifiers

PMID40442409

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.